S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
S&P 500   3,986.27 (+0.38%)
DOW   32,484.20 (+0.77%)
QQQ   308.79 (-0.68%)
AAPL   158.38 (-1.17%)
MSFT   276.25 (-1.54%)
META   202.42 (-1.74%)
GOOGL   102.41 (-2.87%)
AMZN   97.41 (-0.73%)
TSLA   191.71 (+0.68%)
NVDA   265.83 (-0.73%)
NIO   8.92 (-1.65%)
BABA   85.69 (-1.39%)
AMD   96.40 (-1.58%)
T   18.90 (+1.56%)
F   11.52 (+0.09%)
MU   60.01 (-1.88%)
CGC   1.89 (-0.54%)
GE   93.40 (+2.22%)
DIS   95.27 (+1.26%)
AMC   4.40 (-1.57%)
PFE   40.35 (-0.10%)
PYPL   73.47 (-0.55%)
NFLX   325.91 (-0.76%)
NASDAQ:XBIO

Xenetic Biosciences - XBIO Stock Forecast, Price & News

$0.42
+0.03 (+7.65%)
(As of 03/27/2023 01:18 PM ET)
Add
Compare
Today's Range
$0.39
$0.43
50-Day Range
$0.35
$0.73
52-Week Range
$0.24
$1.25
Volume
66,576 shs
Average Volume
60,138 shs
Market Capitalization
$6.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Xenetic Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
918.1% Upside
$4.00 Price Target
Short Interest
Healthy
0.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Xenetic Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars


XBIO stock logo

About Xenetic Biosciences (NASDAQ:XBIO) Stock

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
XBIO Xenetic Biosciences, Inc.
XBIO.PH - | Stock Price & Latest News | Reuters
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Xenetic Biosciences reports Q1 results
See More Headlines
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Company Calendar

Last Earnings
11/11/2021
Today
3/27/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIO
Fax
N/A
Employees
4
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+920.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-5,640,000.00
Net Margins
-383.89%
Pretax Margin
-383.83%

Debt

Sales & Book Value

Annual Sales
$1.71 million
Book Value
$1.37 per share

Miscellaneous

Free Float
14,029,000
Market Cap
$5.95 million
Optionable
Not Optionable
Beta
2.77

Social Links


Key Executives

  • Mr. Jeffrey F. Eisenberg (Age 53)
    CEO & Director
  • Mr. James F. Parslow (Age 54)
    CFO, COO & Corp. Sec.
  • Dr. Curtis A. Lockshin (Age 59)
    Chief Scientific Officer













XBIO Stock - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XBIO shares.
View XBIO analyst ratings
or view top-rated stocks.

What is Xenetic Biosciences' stock price forecast for 2023?

1 analysts have issued 12 month price objectives for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 920.4% from the stock's current price.
View analysts price targets for XBIO
or view top-rated stocks among Wall Street analysts.

How have XBIO shares performed in 2023?

Xenetic Biosciences' stock was trading at $0.2851 at the beginning of 2023. Since then, XBIO stock has increased by 37.5% and is now trading at $0.3920.
View the best growth stocks for 2023 here
.

When is Xenetic Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our XBIO earnings forecast
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The firm earned $0.35 million during the quarter, compared to analysts' expectations of $0.20 million. Xenetic Biosciences had a negative net margin of 383.89% and a negative trailing twelve-month return on equity of 43.49%.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.95%).

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $0.39.

How much money does Xenetic Biosciences make?

Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $5.95 million and generates $1.71 million in revenue each year. The company earns $-5,640,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com.

This page (NASDAQ:XBIO) was last updated on 3/27/2023 by MarketBeat.com Staff